ARTICLE | Company News

Immunovaccine, Incyte deal

August 3, 2015 7:00 AM UTC

The companies partnered non-exclusively to evaluate Immunovaccine’s DPX-Survivac in combination with epacadostat from Incyte plus low-dose oral cyclophosphamide in an open-label Phase Ib trial to treat platinum-sensitive ovarian cancer in about 20 patients who are at a high risk of recurrence. The companies plan to submit an IND for the trial in the U.S. and Canada this year. The companies will share the costs of the trial, which Immunovaccine will conduct. ...